We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+31.56%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$3.85B
AUM Growth
+$887M
Cap. Flow
+$277M
Cap. Flow %
7.2%
Top 10 Hldgs %
72.18%
Holding
61
New
10
Increased
9
Reduced
4
Closed
10
Avg Time Held Equity + Options
6.8 quarters
Top 10 Avg Time Held Equity + Options
5.7 quarters
Top 20 Avg Time Held Equity + Options
6.5 quarters
Avg Time Held Equity only
6.8 quarters
Top 10 Avg Time Held Equity only
5.7 quarters
Top 20 Avg Time Held Equity only
6.5 quarters

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$140M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$92.7M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$80.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$79.9M
5
TNGX icon
Tango Therapeutics
TNGX
+$40M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$131M
2
SWTX icon
SpringWorks Therapeutics
SWTX
+$80M
3
RLAY icon
Relay Therapeutics
RLAY
+$35M
4
MORF icon
Morphic Holding, Inc. Common Stock
MORF
+$30.2M
5
SLRN icon
ACELYRIN
SLRN
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
2 Miscellaneous 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
APLS icon
1
DELISTED
Apellis Pharmaceuticals
APLS
$669M 17.37%
11,173,068
+273,209
+3% +$13.9M
2021 Q4
8 quarters
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$435M 11.28%
7,396,979
+1,648,580
+29% +$92.7M
2023 Q3
1 quarter
PRTA icon
3
Prothena Corp
PRTA
$432M
$421M 10.93%
11,584,280
– –
2018 Q4
20 quarters
ARVN icon
4
Arvinas
ARVN
$443M
$277M 7.19%
6,726,491
+1,259,428
+23% +$29.4M
2021 Q4
8 quarters
LKFT icon
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$234M 6.08%
5,756,268
– –
2021 Q3
9 quarters
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$3.27B
$188M 4.87%
5,991,479
– –
2021 Q4
8 quarters
ANAB icon
7
AnaptysBio
ANAB
$1.39B
$161M 4.18%
7,521,024
– –
2019 Q4
16 quarters
ZYME icon
8
Zymeworks
ZYME
$1.78B
$140M 3.62%
13,437,473
– –
2022 Q4
4 quarters
TNGX icon
9
Tango Therapeutics
TNGX
$3.78B
$132M 3.43%
13,330,736
+4,609,100
+53% +$40M
2020 Q3
13 quarters
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$14B
$125M 3.24%
1,013,952
+645,541
+175% +$80.6M
2023 Q2
2 quarters
ARGX icon
11
argenx
ARGX
$51.9B
$115M 2.97%
+300,997
New +$140M
2023 Q4
0 quarters
XNCR icon
12
Xencor
XNCR
$1.75B
$112M 2.91%
5,282,516
– –
2018 Q4
20 quarters
KURA icon
13
Kura Oncology
KURA
$862M
$83.5M 2.17%
5,806,871
– –
2015 Q4
32 quarters
SRPT icon
14
Sarepta Therapeutics
SRPT
$1.76B
$80.3M 2.09%
+832,907
New +$79.9M
2023 Q4
0 quarters
CRNX icon
15
DELISTED
Crinetics Pharmaceuticals
CRNX
$71.6M 1.86%
2,012,517
+482,254
+32% +$14.8M
2021 Q4
8 quarters
MRSN icon
16
DELISTED
Mersana Therapeutics
MRSN
$44.9M 1.17%
774,588
– –
2023 Q3
1 quarter
CNTA
17
DELISTED
Centessa Pharmaceuticals
CNTA
$44.7M 1.16%
5,618,779
– –
2021 Q2
10 quarters
IMNM icon
18
Immunome
IMNM
$2.08B
$41.5M 1.08%
+3,879,415
New +$32.3M
2023 Q4
0 quarters
EWTX icon
19
Edgewise Therapeutics
EWTX
$3.98B
$38.2M 0.99%
3,493,194
– –
2021 Q1
11 quarters
NMRA icon
20
Neumora Therapeutics
NMRA
$67.6M
$35.3M 0.92%
2,071,450
– –
2023 Q3
1 quarter
THRD icon
21
DELISTED
Third Harmonic Bio
THRD
$34.9M 0.91%
3,182,444
+200,000
+7% +$1.58M
2023 Q1
3 quarters
VYGR icon
22
Voyager Therapeutics
VYGR
$133M
$32.5M 0.84%
3,851,507
– –
2021 Q3
9 quarters
ALEC icon
23
Alector
ALEC
$211M
$32.4M 0.84%
4,056,548
– –
2021 Q1
11 quarters
ORIC icon
24
Oric Pharmaceuticals
ORIC
$1.19B
$31.4M 0.82%
3,418,068
– –
2020 Q2
14 quarters
TCRX icon
25
TScan Therapeutics
TCRX
$15.4M
$29.1M 0.76%
5,000,000
– –
2023 Q2
2 quarters
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2023 Portfolio in Review

As of Q4 2023, EcoR1 Capital held 61 positions worth $3.85B, up 30% from $2.96B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital deployed $277M of net new capital in Q4 2023, opening 10 new positions and adding to 9 existing holdings. Its largest new stake was argenx: 300,997 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Revolution Medicines, an estimated $131M trimmed.

  • EcoR1 Capital's largest Q4 2023 buy was argenx: 300,997 shares worth $115M.
  • EcoR1 Capital added most to Mirati Therapeutics, Inc. Common Stock in Q4 2023, an estimated $92.7M increase.
  • EcoR1 Capital's biggest Q4 2023 reduction was Revolution Medicines, cutting an estimated $131M.
  • EcoR1 Capital fully exited SpringWorks Therapeutics in Q4 2023, selling an estimated $80M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $3.85B portfolio in Q4 2023.
  • EcoR1 Capital opened 10 new positions and closed 10 in Q4 2023.
  • EcoR1 Capital's portfolio value rose 30% quarter-over-quarter to $3.85B.

Based on EcoR1 Capital's 13F filing for Q4 2023, filed 14 Feb 2024.